Clinical Trials
2 trialsNCT06786780 2025-03-26
ECCO
Chongqing University Cancer Hospital
Phase 2 Enrolling by invitation
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation